Results 231 to 240 of about 5,566,486 (385)

Characterizing epithelial‐mesenchymal transition‐linked heterogeneity in breast cancer circulating tumor cells at a single‐cell level

Molecular Oncology, EarlyView.
In over 50% of non‐metastatic breast cancer patients, circulating tumor cells (CTCs) along the whole epithelial‐mesenchymal transition spectrum are detected. Total CTC number and individual phenotypes relate to aggressive disease characteristics, including lymph node involvement and higher tumor proliferation. At the single‐cell level, mesenchymal CTCs
Justyna Topa, Julia Richert, Tomasz Stokowy, Alicja Staśczak, Mariusz Szajewski, Maciej Ciesielski, Petra M. Grešner, Bartłomiej Tomasik, Łukasz Arcimowicz, Agnieszka Stankiewicz, Grażyna Suchodolska, Elżbieta Senkus, Wiesław Kruszewski, Anna J. Żaczek, Aleksandra Markiewicz   +14 more
wiley   +1 more source

Minimal Residual Disease as an Early Endpoint for Accelerated Drug Approval in Myeloma: A Roadmap. [PDF]

Blood Cancer Discov
Landgren O, Devlin SM.
europepmc   +1 more source

Accelerated Approval of Cancer Drugs: Improved Access to Therapeutic Breakthroughs or Early Release of Unsafe and Ineffective Drugs? [PDF]

, 2009
Elizabeth Richey, Erica Lyons, Jonathan R. Nebeker, Veena Shankaran, June M. McKoy, Thanh Ha Luu, Narissa J. Nonzee, Steven Trifilio, Oliver Sartor, Al B. Benson, Kenneth R. Carson, Beatrice J. Edwards, Douglas Gilchrist-Scott, Timothy M. Kuzel, Dennis W. Raisch, Martin S. Tallman, Dennis P. West, Steven Hirschfeld, Antonio J Grillo-López, Charles L. Bennett   +19 more
openalex   +1 more source

The IFNγ‐CIITA‐MHC II axis modulates melanoma cell susceptibility to NK‐cell‐mediated cytotoxicity

Molecular Oncology, EarlyView.
Natural killer (NK) cells play a central role in anti‐melanoma immunity. However, melanoma cells adapt during co‐culture by upregulating CIITA and MHC II in response to interferon gamma (IFNγ), thereby evading NK‐cell lysis. Blocking IFNγ signaling or treatment with dimethyl fumarate/simvastatin counteracts this immune escape and maintains NK‐cell ...
Lena C. M. Krause, Rixa‐Mareike Köhn, Christian Ickes, Julia Lenger, Jonas Fischer, Sabrina Cappello, Ivan Bogeski   +6 more
wiley   +1 more source

Critical insights into the evolving drug-approval process in China. [PDF]

Cancer
Nikanjam M, Kurzrock R.
europepmc   +1 more source

An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC). [PDF]

BMC Cancer, 2022
Sharp J, Prasad V.
europepmc   +1 more source

Minimum requirements for approval of a drug in status epilepticus [PDF]

, 2009
Michel Baulac, Vincent Navarro
openalex   +1 more source

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source

Targeted Therapies, Novel Antibodies, and Immunotherapies in Advanced Non-Small Cell Lung Cancer: Clinical Evidence and Drug Approval Patterns. [PDF]

Clin Cancer Res
Koban MU, Hartmann M, Amexis G, Franco P, Huggins L, Shah I, Karachaliou N.   +6 more
europepmc   +1 more source

New Drug and Biologics Approvals in 2019: A Systematic Analysis of Patient Experience Data in FDA Drug Approval Packages and Product Labels. [PDF]

Ther Innov Regul Sci, 2021
Schultz-Knudsen K, Sabaliauskaite U, Hellsten J, Lassen AB, Morant AV.   +4 more
europepmc   +1 more source